Residual HCV-RNA and Elevated Platelet-to-Lymphocyte Ratio Predict Poor Long-Term Outcomes in Patients with Chronic Hepatitis C After Treatment by Anna Wróblewska, Mateusz Gliwiński, Magda Rybicka, Małgorzata Cheba, Beata Lorenc, Piotr Trzonkowski, Krzysztof P. Bielawski, Katarzyna Sikorska

Subjects: Get full text

Coinfection by Hepatitis C Is Strongly Associated with Abnormal CD4/CD8 Ratio in HIV Patients under Stable ART in Salvador, Brazil by Clara Brites-Alves, Eduardo Martins Netto, Carlos Brites

Get full text

Baseline Serum Cholesterol Is Associated with a Response to Pegylated Interferon Alfa-2b and Ribavirin Therapy for Chronic Hepatitis C Genotype 2 by Naota Taura, Tatsuki Ichikawa, Hisamitsu Miyaaki, Yoshiko Kadokawa, Takuya Tsutsumi, Shotaro Tsuruta, Yuji Kato, Osami Inoue, Noboru Kinoshita, Kazuo Ohba, Hiroyuki Kato, Kazuyuki Ohata, Junichi Masuda, Keisuke Hamasaki, Hiroshi Yatsuhashi, Kazuhiko Nakao

“…A total of 100 chronic hepatitis C patients with HCV genotype 2 who received peg-IFN alfa-2b and ribavirin therapy were consecutively enrolled. …”
Get full text

Economic evaluation of pan-genotypic generic direct-acting antiviral regimens for treatment of chronic hepatitis C in Iran: a cost-effectiveness study by Seyed Moayed Alavian, Mohammad Tasavon Gholamhoseini, Heidar Sharafi, Helena HL Borba, Asma Sabermahani, Behzad Hajarizadeh

“…Introduction Low-cost generic direct-acting antiviral (DAA) regimens for treatment of hepatitis C virus (HCV) are available in several low-income/middle-income countries, important for treatment scale-up. …”
Get full text

Behavioural Risk for HIV, Hepatitis B, and Hepatitis C Infections among a Population of Drug Users and Injectors across Four Regions in Ghana by Chris Guure, Sharren Margaret Obiri-Yeboah Laryea, Samuel Dery, Carlota Baptista da Silva, Comfort Asamoah-Adu, Stephen Ayisi-Addo, Maria-Goretti Loglo, Adamu Mohammed, Kwasi Torpey

“…Blood borne infections such as HIV, Hepatitis B (HBV), and Hepatitis C (HCV) are of great importance to governments and their implementing partners, especially among people who use drugs (PWUD) and people who inject drugs (PWID). …”
Get full text

The impact of genetic polymorphisms of IL28B gene on the efficacy of antiviral therapy of the chronic hepatitis C by using the standard Interferon-<i>α</i> by A. V. Lapshin, M. V. Mayevskaya, V. T. Ivashkin, P. O. Bogomolov, I. G. Nikitin, O. O. Znoyko

Subjects: “…chronic hepatitis c…”
Get full text

Vitamin D Potentiates the Inhibitory Effect of MicroRNA-130a in Hepatitis C Virus Replication Independent of Type I Interferon Signaling Pathway by Xiaoqiong Duan, Yujuan Guan, Yujia Li, Shan Chen, Shilin Li, Limin Chen

Get full text

Frekuensi Hepatitis B dan Hepatitis C Positif pada Darah Donor di Unit Transfusi Darah Cabang Padang pada Tahun 2012 by Dewi Oktavia, Rismawati Yaswir, Nora Harminarti

“…Infeksi virus hepatitis B dan hepatitis C akut bisa bergejala (simptomatik) atau tidak bergejala (asimptomatik). …”
Get full text

Serum Activins and Follistatin during the Treatment of Chronic Hepatitis C Genotypes 1 and 4 and Their Correlations with Viral Load and Liver Enzymes: A Preliminary Report by Bassem Refaat, Adel Galal El-Shemi, Ahmed Mohamed Ashshi, Adnan AlZanbagi

“…To measure the effect of pegylated interferon-α therapy on serum activin-A, activin-B, and follistatin and their correlation with viral load and liver fibrosis in chronic hepatitis C (CHC). Methods. This study was cross-sectional and sera were collected from 165 participants classified into 7 groups: 40 healthy negative control, 33 treatment naïve patients as positive control, 19 patients at week 4, 22 at week 12, and 19 at week 24 of treatment initiation and 21 responders and 11 nonresponders at the end of 48-week treatment protocol. …”
Get full text

Evaluation of Oral Cannabinoid-Containing Medications for the Management of Interferon and Ribavirin-Induced Anorexia, Nausea and Weight Loss in Patients Treated for Chronic Hepatitis C Virus by Cecilia T Costiniuk, Edward Mills, Curtis L Cooper

“…OBJECTIVES: The systemic and cognitive side effects of hepatitis C virus (HCV) therapy may be incapacitating, necessitating dose reductions or abandonment of therapy. …”
Get full text

Association between High-Sensitivity C-Reactive Protein and N-Terminal Pro-B-Type Natriuretic Peptide in Patients with Hepatitis C Virus Infection by Wenliang Che, Buchun Zhang, Wenling Liu, Yidong Wei, Yawei Xu, Dayi Hu

Get full text

Hepatitis C Virus and Nonliver Solid Cancers: Is There an Association between HCV and Cancers of the Pancreas, Thyroid, Kidney, Oral Cavity, Breast, Lung, and Gastrointestinal Tract? by Saad Qadwai, Tayyaba Rehman, Jonathan Barsa, Zeeshan Solangi, Edward Lebovics

“…Hepatitis C virus (HCV) is known for its oncogenic potential and has been found to be associated with hepatocellular carcinoma (HCC) and non-Hodgkin lymphoma. …”
Get full text

Interleukin 28B polymorphism impact on early HCV kinetics in HCV-infected liver transplant recipients undergoing antiviral therapy by V. E. Syutkin, V. P. Chulanov, I. V. Karandashova, V. A. Dolgin, A. O. Chugunov

Subjects: Get full text

The combined therapy of chronic hepatitis with pegilated interferon <i>a</i>-2а and ribavirin in patients with HIV-infection and patients with HCV monoinfection by N. D. Yuschuk, S. L. Maximov, L. M. Ivanova, Ye. K. Klimova, O. O. Znoyko, A. V. Kravchenko

Subjects: “…chronic hepatitis c…”
Get full text

Virus-Mimicking Polymer Nanocomplexes Co-Assembling HCV E1E2 and Core Proteins with TLR 7/8 Agonist—Synthesis, Characterization, and In Vivo Activity by Thomas R. Fuerst, Alexander Marin, Sarah Jeong, Liudmila Kulakova, Raman Hlushko, Katrina Gorga, Eric A. Toth, Nevil J. Singh, Alexander K. Andrianov

Subjects: Get full text

Efficacy and safety of the Russian protease inhibitor narlaprevir at treatment-naive and earlier treated noncirrhotic patients with the 1st genotype chronic hepatitis C (PIONEER study) by M. V. Mayevskaya, V. T. Ivashkin, O. O. Znoyko, Ye. A. Klimova, D. T. Abdurakhmanov, I. G. Bakulin, P. O. Bogomolov, E. Z. Burnevich, M. Yu. Galushko, N. I. Geyvandova, K. V. Zhdanov, Ye. V. Esaulenko, S. N. Kizhlo, D. Yu. Konstantinov, N. I. Mironova, V. G. Morozov, Ye. A. Strebkova, I. G. Nikitin, M. F. Osipenko, V. D. Pasechnikov, O. I. Sagalova, I. M. Khayertynova, V. P. Chulanov, A. A. Yakovlev, I. A. Vasyutin, Ye. P. Tarkhova, E. N. Krasavina, M. Yu. Samsonov

“…To estimate efficacy and safety of narlaprevir (NVR) with ritonavir (RTV), pegilated interferon (peg-IFN) and ribavirin (RBV) at treatmentnaïve and earlier treated noncirrhotic patients with chronic hepatitis C caused by the 1st virus genotype in double blind placebo-controlled 3rd phase study (PIONEER). …”
Get full text

The Efficacy of On-Site Integration Screening and Microelimination Programs for Chronic Hepatitis C in a Detection Center: A Comparison of the Treatment Outcomes and Characteristics of Incarcerated Patients and Outpatients by Hsuan-Yuan Chang, Su-Hung Wang, Hsing-Tao Kuo, Ming-Jen Sheu, I-Che Feng, Chung-Han Ho, Jui-Yi Chen, Chi-Shu Sun, Chi-Hsing Chen, Cheng-Yi Lin, Chun-Chi Yang

“…We aimed to analyze the different patient characteristics and treatment outcomes (such as sustained viral response, SVR) between incarcerated patients with chronic hepatitis C (CHC) and those with CHC from the outpatient department through an on-site integrated screening and microelimination program in a detection center. …”
Get full text

Treatment of Chronic Hepatitis C Infection among Current And Former Injection Drug Users within a Multidisciplinary Treatment Model at a Community Health Centre by Adam I Newman, Shelley Beckstead, David Beking, Susan Finch, Tina Knorr, Carol Lynch, Meredith MacKenzie, Daphne Mayer, Brenda Melles, Ron Shore

“…The aim of the present prospective observational study was to assess uptake and success of hepatitis C virus (HCV) treatment among a group of former and current injection drug users with chronic HCV infection at the Street Health Centre in Kingston, Ontario. …”
Get full text

Changes in DNA methylation profile in liver tissue during progression of HCV-induced fibrosis to hepatocellular carcinoma by I. A. Goncharova, A. A. Zarubin, N. P. Babushkina, I. A. Koroleva, M. S. Nazarenko

Subjects: Get full text

Combined Liver Stiffness and Α-fetoprotein Further beyond the Sustained Virologic Response Visit as Predictors of Long-Term Liver-Related Events in Patients with Chronic Hepatitis C by Sheng-Hung Chen, Hsueh-Chou Lai, Wen-Pang Su, Jung-Ta Kao, Po-Heng Chuang, Wei-Fan Hsu, Hung-Wei Wang, Tsung-Lin Hsieh, Hung-Yao Chen, Cheng-Yuan Peng

“…Long-term risk stratification using combined liver stiffness (LS) and clinically relevant blood tests acquired at the baseline further beyond the sustained virologic response (SVR) visit for chronic hepatitis C (CHC) has not been thoroughly investigated. …”
Get full text